Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05878067 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
NCT05878067 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 40 participants.
The verdict
NCT05878067, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
Study Summary
Dry Eye Disease (DED) is a condition where the tear film of the eye becomes unstable and along with ocular surface inflammation and damage leads to inadequate tear production and eye lubrication. This study will evaluate symptom relief and tolerability of ABBV-444 eye drops in adult participants. ABBV-444 is being developed for the treatment of Dry Eye Disease (DED). This is a 30-day, open-label study to evaluate adult participant symptoms and tolerability of ABBV-444. Around 40 participants will be enrolled in 1 site in the United States. Participants will receive 1-2 drops of ABBV-444 in each eye as needed but minimally twice a day for 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.
Interventions
- DRUG ABBV-444
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-06-27 |
| Est. Completion | 2023-10-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05878067
The ClinicalTrials.gov registry entry for NCT05878067 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABBV-444 is the first listed.
NCT05878067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05878067 about?
NCT05878067 is a clinical study titled "A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants". Dry Eye Disease (DED) is a condition where the tear film of the eye becomes unstable and along with ocular surface inflammation and damage leads to inadequate tear production and eye lubrication. This study will evaluate symptom relief and tolerability of ABBV-444 eye drops in adult participants. A...
What is the current status of trial NCT05878067?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2023-06-27. Estimated completion is 2023-10-06.
What interventions are being tested in trial NCT05878067?
The interventions under investigation include: ABBV-444 (DRUG).
Who is sponsoring clinical trial NCT05878067?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.